BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27468826)

  • 1. Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor - belinostat - in glioblastoma cell lines: a preliminary report.
    Kusaczuk M; Krętowski R; Stypułkowska A; Cechowska-Pasko M
    Invest New Drugs; 2016 Oct; 34(5):552-64. PubMed ID: 27468826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenylbutyrate-a pan-HDAC inhibitor-suppresses proliferation of glioblastoma LN-229 cell line.
    Kusaczuk M; Krętowski R; Bartoszewicz M; Cechowska-Pasko M
    Tumour Biol; 2016 Jan; 37(1):931-42. PubMed ID: 26260271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.
    Marlow LA; Bok I; Smallridge RC; Copland JA
    Endocr Relat Cancer; 2015 Oct; 22(5):777-92. PubMed ID: 26206775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.
    Savickiene J; Treigyte G; Valiuliene G; Stirblyte I; Navakauskiene R
    Anticancer Drugs; 2014 Sep; 25(8):938-49. PubMed ID: 24800886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer clinical efficiency and stochastic mechanisms of belinostat.
    El Omari N; Bakrim S; Khalid A; Albratty M; Abdalla AN; Lee LH; Goh KW; Ming LC; Bouyahya A
    Biomed Pharmacother; 2023 Sep; 165():115212. PubMed ID: 37541175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
    Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
    Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
    Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells.
    Bajbouj K; Mawrin C; Hartig R; Schulze-Luehrmann J; Wilisch-Neumann A; Roessner A; Schneider-Stock R
    J Neurooncol; 2012 May; 107(3):503-16. PubMed ID: 22270849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells.
    Yang L; Liang Q; Shen K; Ma L; An N; Deng W; Fei Z; Liu J
    Biomed Pharmacother; 2015 Apr; 71():70-8. PubMed ID: 25960218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
    Patra N; De U; Kim TH; Lee YJ; Ahn MY; Kim ND; Yoon JH; Choi WS; Moon HR; Lee BM; Kim HS
    Biomed Pharmacother; 2013 Jun; 67(5):407-15. PubMed ID: 23583193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belinostat, a potent HDACi, exerts antileukaemic effect in human acute promyelocytic leukaemia cells via chromatin remodelling.
    Valiuliene G; Stirblyte I; Cicenaite D; Kaupinis A; Valius M; Navakauskiene R
    J Cell Mol Med; 2015 Jul; 19(7):1742-55. PubMed ID: 25864732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TSA suppresses miR-106b-93-25 cluster expression through downregulation of MYC and inhibits proliferation and induces apoptosis in human EMC.
    Zhao ZN; Bai JX; Zhou Q; Yan B; Qin WW; Jia LT; Meng YL; Jin BQ; Yao LB; Wang T; Yang AG
    PLoS One; 2012; 7(9):e45133. PubMed ID: 23028803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
    Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
    Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDAC inhibitor M344 suppresses MCF-7 breast cancer cell proliferation.
    Yeung A; Bhargava RK; Ahn R; Bahna S; Kang NH; Lacoul A; Niles LP
    Biomed Pharmacother; 2012 Apr; 66(3):232-6. PubMed ID: 22436652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer.
    Dovzhanskiy DI; Arnold SM; Hackert T; Oehme I; Witt O; Felix K; Giese N; Werner J
    BMC Cancer; 2012 Jun; 12():226. PubMed ID: 22681698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.
    Mandl-Weber S; Meinel FG; Jankowsky R; Oduncu F; Schmidmaier R; Baumann P
    Br J Haematol; 2010 May; 149(4):518-28. PubMed ID: 20201941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
    Tula-Sanchez AA; Havas AP; Alonge PJ; Klein ME; Doctor SR; Pinkston W; Glinsmann-Gibson BJ; Rimsza LM; Smith CL
    Cancer Biol Ther; 2013 Oct; 14(10):949-61. PubMed ID: 23982416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAC Inhibitor Oxamflatin Induces Morphological Changes and has Strong Cytostatic Effects in Ovarian Cancer Cell Lines.
    Wang YL; Liui HL; Fu RG; Wang ZW; Ren HT; Dai ZJ; Jing YY; Li Y
    Curr Mol Med; 2016; 16(3):232-42. PubMed ID: 26917266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
    Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
    Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An appraisal of cinnamyl sulfonamide hydroxamate derivatives (HDAC inhibitors) for anti-cancer, anti-angiogenic and anti-metastatic activities in human cancer cells.
    Reddy ND; Shoja MH; Biswas S; Nayak PG; Kumar N; Rao CM
    Chem Biol Interact; 2016 Jun; 253():112-24. PubMed ID: 27163855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.